ReviewJournal of immunotherapy and precision oncology2026
Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer.
Review in Journal of immunotherapy and precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common non-cutaneous malignancy affecting men in the United States, with the incidence of metastatic disease rising. Despite modern androgen deprivation therapy (ADT), nearly all cases of metastatic prostate cancer develop castration resistance. Informed by successes in the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment modalities have emerged as part of the armamentarium for metastatic hormone-sensitive prostate cancer (mHSPC). In this review, we detail treatments such as cytotoxic chemotherapy, androgen receptor pathway inhibitors (ARPIs), radiotherapy, radiopharmaceutical therapy, immunotherapy, and poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of mHSPC, synthesizing current evidence and guiding clinical decision-making. With technological advances and insight from molecular studies, we discuss emerging biomarkers as indicators to guide prognostication and therapeutic decisions. As a result of these developments, the treatment landscape for mHSPC is evolving toward a precision oncology paradigm incorporating combined systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.